Speakers

Dr. Shireen Sindi is a neuroscientist and Associate Professor at Karolinska Institutet whose work focuses on dementia prevention and healthy brain aging. Her research integrates epidemiology, multi-system biomarkers, and lifestyle intervention studies to identify modifiable risk and resilience factors. A key focus of her work is advancing understanding of sex and gender differences in Alzheimer’s disease and related dementias. Through large-scale studies and international collaborations, she aims to develop tailored, evidence-based strategies that advance equitable dementia prevention and promote brain health.

Dr Uzgiris leads the Center for Innovation in Diagnostics in North America. His work focuses on integrating in vitro diagnostic assays, advanced imaging modalities, and machine-learning approaches to enable earlier and more precise detection of neurodegenerative, cardiovascular, oncologic, and infectious diseases.

He played a key scientific role in translating neurofilament light chain (NfL) testing into clinical trials for multiple sclerosis, ALS, and Alzheimer’s disease through major collaborations with Biogen, Novartis, and Johns Hopkins University, helping establish NfL as a leading blood-based biomarker of neuronal injury.

A recognized thought leader in diagnostic innovation, Dr. Uzgiris also serves as faculty for the 2026 ADLM Disruptive Technology Award program, where he contributes expertise on the future of precision diagnostics and next-generation biomarker development.

Manu Vandijck is Product Development Manager at Fujirebio Europe NV, where he leads development of next‑generation neurodegeneration biomarkers, including plasma and CSF assays supporting early and accurate Alzheimer’s disease diagnosis. He has played a key role in advancing automated Lumipulse® assays for pTau181 and pTau217, contributing to improved detection of Alzheimer’s pathology through blood‑ and CSF‑based measures.

His work includes leading presentations at international Alzheimer’s and Parkinson’s conferences, where he has showcased innovations such as the Lumipulse G pTau217/β‑amyloid 1‑42 plasma ratio and performance evaluations of prototype assays. He is also a co‑author on influential Alzheimer’s biomarker research, including studies on standardizing CSF biomarker handling and improving alignment of diagnostic assays with reference LC‑MS/MS methods.

His contributions support global efforts to bring reliable, scalable, and clinically actionable biomarker tools into practice, helping to accelerate early detection and trial readiness in Alzheimer’s disease.

Dr. Natalia Vilor-Tejedor is a statistical genetic epidemiologist and neuroscientist investigating the molecular determinants of brain health across the lifespan. She leads the Molecular Epidemiology and Data Science Group at the Institute for Risk Assessment Sciences (Utrecht University) and the Barcelonaβeta Brain Research Center, where her team integrates multi-omics, exposomic profiling, and advanced statistical modeling to identify risk and resilience mechanisms that enable precision prevention and personalized medicine.

Dr. Henrik Zetterberg, a distinguished figure in the field of neurochemistry, He serves as Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and is a Clinical Chemist at Sahlgrenska University Hospital. He also leads the UK DRI Fluid Biomarker Laboratory at UCL and holds visiting professorships in international neurodegeneration research programs.

Dr. Zetterberg is a global leader in the development of fluid biomarkers for Alzheimer’s disease and related dementias, contributing foundational discoveries that have reshaped early diagnosis and disease monitoring. His work spans CSF and blood-based biomarkers—pioneering assays that can detect Alzheimer’s pathology with high accuracy, years before symptoms emerge.

He has authored more than 1,800 scientific publications, received numerous prestigious awards, and continues to drive innovation in biomarker science, clinical diagnostics, and translational